- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Latest guidelines on diagnosing hypersensitivity pneumonitis by ATS
The American Thoracic Society - in collaboration with the Asociacion Latinoamericana de Torax or ALAT and the Japanese Respiratory Society- has developed new guidelines on the clinical evaluation of hypersensitivity pneumonitis (HP) for clinicians. The guidelines are available online ahead of print in the American Journal of Respiratory and Critical Care Medicine.
Hypersensitivity pneumonitis manifests as interstitial lung disease. It is difficult to diagnose and until now, there has been little consensus in terms of disease definition, diagnostic criteria and diagnostic approach.
"The clinician is often unable to distinguish features of fibrotic HP (f-HP) from those of idiopathic pulmonary fibrosis (IPF), and some patients meeting the criteria for the diagnosis of IPF may in fact have f-HP with pulmonary fibrosis," said Ganesh Raghu, MD, professor of medicine, University of Washington and director of the Center for Interstitial Lung Disease at University of Washington Medical center. "The high rate of screen failures in patients participating in IPF clinical trials highlights this diagnostic challenge, as pulmonologists may be misdiagnosing patients with f-HP as having IPF, overlooking environmental factors that can contribute to the disease."
The guideline committee categorized HP into two clinical phenotypes, namely nonfibrotic and fibrotic HP, and made recommendations for reach. Their priority was to help clinicians make a confident and accurate diagnosis of HP.
The following is a summary of the panel's recommendations, which were formulated using the Grading of Recommendations, Assessment, Development, and Evaluation approach (GRADE):
Recommendation 1
- For patients with newly identified ILD whose differential diagnosis includes non-fibrotic HP or fibrotic HP, the guideline committee makes no recommendation or suggestion for or against the use of a specific questionnaire to identify potential inciting agents of HP; instead, the guideline committee recommends the development and validation of a questionnaire. Remark: Pending the availability of a validated questionnaire, the guideline committee advocates that clinicians take a thorough history to identify potential exposures and sources in the patient's environment that are known to be associated with HP.
Recommendation 2
- For patients with newly identified ILD whose differential diagnosis includes non-fibrotic HP, the guideline committee suggests performing serum IgG testing that targets potential antigens associated with HP (suggestion, very low confidence in the estimated effects).
- For patients with newly identified ILD whose differential diagnosis includes fibrotic HP, the guideline committee suggests performing serum IgG testing that targets potential antigens associated with HP (suggestion, very low confidence in the estimated effects).
Recommendation 3
- For patients with newly identified ILD whose differential diagnosis includes non-fibrotic HP, the guideline committee recommends bronchoalveolar lavage with lymphocyte cellular analysis (recommendation, very low confidence in the estimated effects).
- For patients with newly identified ILD whose differential diagnosis includes fibrotic HP, the guideline committee suggests bronchoalveolar lavage with lymphocyte cellular analysis (suggestion, very low confidence in the estimated effects).
Recommendation 4
- For patients with newly identified ILD whose differential diagnosis includes non-fibrotic HP, the guideline committee suggests transbronchial forceps lung biopsy (suggestion, very low confidence in the estimated effects).
- For patients with newly identified ILD whose differential diagnosis includes fibrotic HP, the guideline committee makes no recommendation or suggestion for or against transbronchial forceps lung biopsy.
Recommendation 5
- For patients with newly identified ILD whose differential diagnosis includes non-fibrotic HP, the guideline committee makes no recommendation or suggestion for or against transbronchial cryobiopsy.
- For patients with newly identified ILD whose differential diagnosis includes fibrotic HP, the guideline committee suggests transbronchial cryobiopsy (suggestion, very low confidence in estimated effects).
Recommendation 6
- For patients with newly identified ILD whose differential diagnosis includes non-fibrotic HP, the guideline committee suggests surgical lung biopsy; this recommendation is intended for after alternative diagnostic options have been exhausted (suggestion, very low confidence in estimated effects).
- For patients with newly identified ILD whose differential diagnosis includes fibrotic HP, the guideline committee suggests surgical lung biopsy; this recommendation is intended for after alternative diagnostic options have been exhausted (suggestion, very low confidence in estimated effects).
"These guidelines create a framework that we hope will standardize clinical care and facilitate research," said Kevin C. Wilson, MD, professor of medicine at Boston University School of Medicine. Dr. Wilson also oversees development of clinical practice guidelines for the ATS.
The ATS has published nearly 20 clinical practice guidelines on various conditions, ranging from allergy and asthma to TB, other pulmonary infections and including IPF, a disease often mistaken for f-HP. For ATS guideline implementation tools and derivatives, go here.
Hina Zahid Joined Medical Dialogue in 2017 with a passion to work as a Reporter. She coordinates with various national and international journals and association and covers all the stories related to Medical guidelines, Medical Journals, rare medical surgeries as well as all the updates in the medical field. Email:Â editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751